CCR4

August 28, 2017August 28, 2017

FDA Grants Breakthrough Therapy Status to Lymphoma Treatment Poteligeo

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to Poteligeo (mogamulizumab) as a treatment for mycosis fungoides and sézary syndrome, the most common subtypes of cutaneous T-cell lymphoma, ... Read more

August 19, 2016August 19, 2016

T-cell Lymphoma/Leukemia Patients Eligible for HSCT Cautioned on Use of Poteligeo

News

Patients with adult T-cell leukemia/lymphoma (ATLL) who were treated with Poteligeo (mogamulizumab), an anti-CCR4 monoclonal antibody, may be at higher risk for serious graft-versus-host disease (GvHD)-related complications following allogeneic hematopoietic stem ... Read more

June 13, 2016June 13, 2016

Mogamulizumab More Effective Than Chemotherapy for Adult T-Cell Leukemia-Lymphoma, Study Finds

News

Results from a Phase 2 clinical trial demonstrate that the drug mogamulizumab promotes better response rates than standard chemotherapy in patients with a rare form of cancer, called relapsed of refractory adult T-cell leukemia-lymphoma ... Read more